FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data highlighting the value of its IDgenetix pharmacogenomic (PGx) test in guiding medication recommendations for patients with mental health conditions who are 65 and older. The data will be shared via a poster presentation at the 2024 American Association for Geriatric Psychiatry (AAGP) Annual Meeting, taking place March 15-18 in Atl ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 11:15 a.m. Eastern time. A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir. ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will share data across its dermatologic portfolio of gene expression profile (GEP) tests via oral and electronic poster presentations at the 2024 AAD Annual Meeting, taking place March 8-12 in San Diego. “Our presentations at the 2024 AAD Annual Meeting add to the growing body of evidence supporting the use of our tests in guidi ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new multi-center performance study of its DecisionDx-SCC risk stratification test. The study, published in Dermatology and Therapy and available here, analyzed the independent performance of DecisionDx-SCC from risk factors and traditional staging systems (i.e., Brigham and Women’s Hospital (BWH) and American Joint Com ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - President, CEO, Founder & Director Frank Stokes - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Brandon Kramer - Guggenheim Securities Sung Ji Nam - Scotiabank Tom Peterson - Baird Jacob Krahenbuhl - Stephens Thomas Flaten - Lake Street Operator Good afternoon, and welcome to Castle Biosciences Fourth Quarte ...

Castle Biosciences, Inc. (CSTL) reported $66.12 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 72.5%. EPS of -$0.10 for the same period compares to -$0.78 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $51.32 million, representing a surprise of +28.85%. The company delivered an EPS surprise of +88.10%, with the consensus EPS estimate being -$0.84.While investors scrutinize revenue and earnings changes year-over-year and how they ...

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.78 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 88.10%. A quarter ago, it was expected that this company would post a loss of $0.92 per share when it actually produced a loss of $0.26, delivering a surprise of 71.74%.Over the last four quarters, the company has ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-38984 CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in Cancers1 demonstrating that DecisionDx-Melanoma provided significantly better risk stratification than American Joint Committee on Cancer 8th Edition (AJCC8) staging in patients with stage I cutaneous melanoma (CM). This study reports the results of two large stage I cohorts, including 5,651 patients from the ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2023, after the close of market on Wednesday, Feb. 28, 2024. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast o ...